-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

64th ASH Annual Meeting and Exposition

Thursday, December 8, 2022

Thursday | Friday | Saturday | Sunday | Monday | Tuesday | Wednesday | Thursday | top

3:00 PM-7:00 PM


ASH COVID-19 Testing Center (for in-person participants)  
Events


ASH COVID-19 Testing Center (for in-person participants)  
Events


Registration (for in-person participants)  
Events

Friday, December 9, 2022

Thursday | Friday | Saturday | Sunday | Monday | Tuesday | Wednesday | Thursday | top

7:00 AM-10:00 AM


A Thread to Pull: Unraveling the Complexities of Myeloid Malignancies  
Friday Satellite Symposia


Demystifying Cold Agglutinin Disease: A Visual Exploration of Mechanism, Diagnosis, and the Role of Complement Inhibition in Addressing Unmet Needs  
Friday Satellite Symposia


Fixing the Target on Aggressive Lymphoma: Insights on the Next Phase of Integrating Targeted Agents into MCL and DLBCL Management  
Friday Satellite Symposia


Maintaining ‘Intensity’ for Better Outcomes in AML: Guidance on Modern, Intensive Upfront Platforms in Challenging Patient Populations  
Friday Satellite Symposia


Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms into Patient Care  
Friday Satellite Symposia


The Rising Tide of CAR-T in Lymphoma: Guidance on Leveraging Cellular Therapy to Improve Outcomes Across the Spectrum of Care  
Friday Satellite Symposia


The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes  
Friday Satellite Symposia


The Sequel to the Targeted Therapy Era in CML: Guidance on Sequential Care and Integrating Established and Novel Options into Cohesive Management Plans  
Friday Satellite Symposia


The Winning Way with BTK Inhibitors in CLL: Evidence-Informed Choices on Treatment Selection, Safety, and Therapeutic Sequencing  
Friday Satellite Symposia

7:00 AM-6:00 PM


ASH COVID-19 Testing Center (for in-person participants)  
Events


ASH COVID-19 Testing Center (for in-person participants)  
Events


Registration (for in-person participants)  
Events

9:00 AM-11:00 AM


2022 World Cup Soccer Viewing (Outdoors)  
Events

9:00 AM-12:00 PM


Training Program Directors' Workshop  
Special-Interest Sessions

11:00 AM-2:00 PM


A Conversation With the Myeloma Experts: Making Sense of the Evolving Treatment Landscape  
Friday Satellite Symposia


Acute Lymphoblastic Leukemia Data and Case Discussion on the Use of Asparaginase Therapy in Young and Older Adults  
Friday Satellite Symposia


Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia - What Clinicians Want to Know (Part 1 of a 3-part CME-accredited Symposia Series)  
Friday Satellite Symposia


Advances in the Treatment of T-Cell Lymphomas: A Forum for Data and Case Discussion  
Friday Satellite Symposia


Amplifying the Role of Accurate Diagnosis and New Therapeutic Options in the Treatment of Hemolytic Anemias  
Friday Satellite Symposia


An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management Approaches  
Friday Satellite Symposia


Bridging Clinical Gaps in Indolent and Aggressive B-Cell Lymphomas: The Investigators Demonstrate How Novel Mechanisms Will Impact Your Practice Tomorrow  
Friday Satellite Symposia


Complement Clinical Cases: Navigating Care for Patients with aHUS, PNH, and HSCT-TMA  
Friday Satellite Symposia


Elevating Equity in Caring For Patients With Hematologic Malignancies  
Friday Satellite Symposia


Expert Illustrations and Commentaries™: Visualizing New Treatment Pathways for Anemia in Chronic Kidney Disease  
Friday Satellite Symposia


How We Do It™: Application of State-of-the-Art MF and PV Care Today... With An Eye Toward How New Evidence and Combinations Will be Leveraged Tomorrow  
Friday Satellite Symposia


MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes  
Friday Satellite Symposia


Navigating a Changing Landscape Together: Gene Therapy for Hemophilia  
Friday Satellite Symposia


Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care with Groundbreaking Treatment  
Friday Satellite Symposia


Medical Crossfire®: How The Experts Treat Acute Lymphoblastic Leukemia: Case Discussions from Adolescent to Adult  
Friday Satellite Symposia


Practice-Changing Data in Relapsed/Refractory Diffuse Large B-Cell Lymphoma—Integrating New Treatments  
Friday Satellite Symposia


Rapidly Evolving Paradigms in Multiple Myeloma: Applying Current Data in the Clinic  
Friday Satellite Symposia


State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections  
Friday Satellite Symposia


Taking Stock of the Evolving Treatment Landscape for Acute GvHD in HSCT  
Friday Satellite Symposia


Transforming How We Treat Sickle Cell Disease: Holistic Approaches to Addressing Clinical Challenges Across the Patient’s Lifespan  
Friday Satellite Symposia


Understanding the Biology and Addressing the Management Challenges of Cytopenic Myelofibrosis  
Friday Satellite Symposia

12:30 PM-5:00 PM

Trainee Activities and Services

ASH-a-Palooza
Trainee Activities and Services

1:00 PM-3:00 PM


2022 World Cup Soccer Viewing (Outdoors)  
Events

2:00 PM-5:00 PM

Scientific Workshops

Scientific Workshop on Advancing Decentralized Clinical Trials in Hematology
Scientific Workshops

Scientific Workshop on Bedside to Bench: Dissecting Emergent CAR T-cell Toxicities beyond CRS and ICANS
Scientific Workshops

Scientific Workshop on Gene Editing in Hematology: Here to Stay
Scientific Workshops

Scientific Workshop on Germline Predisposition to Hematopoietic Malignancies and Bone Marrow Failure
Scientific Workshops

Scientific Workshop on Hematology and Aging
Scientific Workshops

Scientific Workshop on Interplay between Coagulation and Malignancy
Scientific Workshops

Scientific Workshop on Leveraging Digital Technology to Modernize and Enhance Observational Studies
Scientific Workshops

Scientific Workshop on Myeloid Development
Scientific Workshops

Scientific Workshop on Thrombotic Microangiopathies
Scientific Workshops

Scientific Workshop on Translational Molecular Diagnostics: Genomic Reclassification of Blood Cancer
Scientific Workshops

3:00 PM-6:00 PM


Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma - What Clinicians Want to Know (Part 2 of a 3-part CME-accredited Symposia Series)  
Friday Satellite Symposia


Aggressive B-Cell Lymphomas: Experts Discuss New Care Standards and Evolving Treatment Strategies  
Friday Satellite Symposia


AL Amyloidosis: Advances in Early Diagnosis, Treatment Options, and Individualized Care  
Friday Satellite Symposia


A Review of Next-Generation Therapeutics and Contemporary Management of Myelofibrosis  
Friday Satellite Symposia


Challenging Cases in Relapsed/Refractory Follicular Lymphoma  
Friday Satellite Symposia


'D' is for Diagnosis: Deciphering Uncommon Hematologic Disorders Through the Eyes of a Detective  
Friday Satellite Symposia


A Light at the End of the Treatment Tunnel – Exploring the Potential Role for Gene Therapy in Hemophilia B  
Friday Satellite Symposia


JAK Inhibitors in Myelofibrosis: Expert Insights on Cases in Personalizing Therapy  
Friday Satellite Symposia


Let’s Talk About Sickle Cell Disease: Perspectives, Case Challenges, and Clinical Pearls  
Friday Satellite Symposia


Let’s Talk: Community Perspectives on Acute Myeloid Leukemia and Myelodysplastic Syndrome  
Friday Satellite Symposia


Medical Crossfire®: Maximizing Our Clinical Practices for Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings  
Friday Satellite Symposia


Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy  
Friday Satellite Symposia


The Future is Now in MDS: Guidance on Integrating Innovative, Risk-Adapted Therapeutic Options into Patient Management  
Friday Satellite Symposia

7:00 PM-10:00 PM


Addressing Current Questions and Controversies in the Management of Multiple Myeloma - What Clinicians Want to Know (Part 3 of a 3-part CME-accredited Symposia Series)  
Friday Satellite Symposia


Breakthrough Therapeutics for CLL and Other B-Cell Malignancies: Focus on BTK Inhibitors From Development to Clinical Integration  
Friday Satellite Symposia


Medical Crossfire®: How Do We Apply the Latest Evidence on Novel Therapies to Prevent and Treat GvHD?  
Friday Satellite Symposia


Transfusion-Related Iron Overload – Evidence-Based Approaches to Improve Chelation Outcomes  
Friday Satellite Symposia

Saturday, December 10, 2022

Thursday | Friday | Saturday | Sunday | Monday | Tuesday | Wednesday | Thursday | top

7:00 AM-7:45 AM


ASH Yoga  
ASH Wellness Studio

7:00 AM-6:00 PM


ASH COVID-19 Testing Center (for in-person participants)  
Events


ASH COVID-19 Testing Center (for in-person participants)  
Events


Registration (for in-person participants)  
Events

8:00 AM-9:00 AM


Acute Myeloid Leukemia Genomics  
Meet the Scientist


CANCELLED: Sickle Cell Disease – Where do Gene Therapy and Hematopoietic Cell Transplantation Fit into the Future Landscape  
How I Treat: Bringing Science to Clinical Dilemmas


Can We Move Toward a Precision Medicine Approach for the Treatment of Higher Risk Myelodysplastic Syndromes  
How I Treat: Bringing Science to Clinical Dilemmas


Clonal Analysis of Dnmt3a-mutant Premalignant Hematopoiesis  
Meet the Scientist


Coffee and Collaboration in ASH Central (for in-person participants)  
Events


Hemoglobin Switching  
Meet the Scientist


ITP/TTP – and Other Scary Causes of Thrombocytopenia - Saturday  
How I Treat: Bringing Science to Clinical Dilemmas


T Cell Exhaustion  
Meet the Scientist


The Case for MRD Testing and the Relevance to Treatment Decisions and Outcomes in AML.  
How I Treat: Bringing Science to Clinical Dilemmas

9:00 AM-9:30 AM


Coffee Break in Poster Hall (for in-person participants)  
Events


Defining Inequity and Root Causes of Health Inequities  
Health Equity Studio

9:00 AM-1:00 PM


2022 World Cup Soccer Viewing (Outdoors)  
Events

9:00 AM-7:30 PM


Poster Session I - Viewing  
Events

9:05 AM-9:15 AM


Bringing Joy to Your World  
ASH Wellness Studio

9:15 AM-9:25 AM


Breathe Well to Feel Well  
ASH Wellness Studio

9:30 AM-10:45 AM


Aplastic Anemia, Dysimmunity and Mutant Clones  
Scientific Program


Autoimmune Hemolytic Anemias (AIHA)  
Education Program


Controversies in Aggressive NHL  
Education Program


Emerging Technologies in Hemostasis  
Scientific Program


JAK/STAT Inhibition and Beyond in Ph Negative MPNs  
Education Program


Multiple Myeloma: Assessing the Patient and the Disease  
Education Program

9:30 AM-11:00 AM


114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Novel Therapies  
Oral and Poster Abstracts


201. Granulocytes, Monocytes, and Macrophages II  
Oral and Poster Abstracts


311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Special Populations and Long-term Outcomes in ITP  
Oral and Poster Abstracts


322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Practice-changing Information from Datasets and Registries on Bleeding Disorders I  
Oral and Poster Abstracts


401. Blood Transfusion: Molecular Mechanisms and Novel Therapies  
Oral and Poster Abstracts


602. Myeloid Oncogenesis: Basic: Therapeutic Targeting of Myeloid Malignancies  
Oral and Poster Abstracts


604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Therapeutic Vulnerabilities Triggering Mechanisms of Drug Resistance and Sensitivity in Myeloid Neoplasms  
Oral and Poster Abstracts


612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Management of Novel ALL Subsets in Different Age Groups  
Oral and Poster Abstracts


613. Acute Myeloid Leukemias: Clinical and Epidemiological: Innovations in Prognostication for Patients with Acute Myeloid Leukemia  
Oral and Poster Abstracts


616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Relapsed/Refractory AML  
Oral and Poster Abstracts


622. Lymphomas: Translational–Non-Genetic: Tumor Microenvironment in Lymphoid Malignancies: Composition, Biology, and Prognostic Significance  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological I  
Oral and Poster Abstracts


632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Agents  
Oral and Poster Abstracts


636. Myelodysplastic Syndromes—Basic and Translational: Clonal Trajectories and Novel Therapies  
Oral and Poster Abstracts


642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Doublet Combinations  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational I  
Oral and Poster Abstracts


652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Precursor States: MGUS and Smoldering Myeloma  
Oral and Poster Abstracts


722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Clinical Studies Exploring the Immunobiology of HCT  
Oral and Poster Abstracts


731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP  
Oral and Poster Abstracts


801. Gene Therapies: Addressing Challenges & Opportunities in Pre-clinical Settings  
Oral and Poster Abstracts


903. Health Services and Quality—Myeloid Malignancies I  
Oral and Poster Abstracts

11:00 AM-12:30 PM


Live Music and Outdoor Lunch Seating (for in-person participants)  
Events


Open Time for Lunch  
Events

11:00 AM-5:00 PM


Exhibits Open  
Events

11:05 AM-11:15 AM


Money Issues are Burning You Out  
ASH Wellness Studio

11:15 AM-11:45 AM


Overcoming Lack of Diversity in Clinical Trials  
Health Equity Studio

11:15 AM-12:15 PM


Career Development Lunch (for in-person participants)
Trainee Activities and Services


Blood Presents: How to get Published in a Peer Review Journal  
Special-Interest Sessions


Grassroots Network Lunch  
Special-Interest Sessions

11:20 AM-11:30 AM


One Breath to the Most Kind, Compassionate, and Grateful You!  
ASH Wellness Studio

11:30 AM-12:30 PM


Are higher factor levels a rising consideration when selecting a hemophilia treatment?  
Product Theaters


Data Worth Stopping For: New 5-year Follow-Up Data for an Oral-Based CLL Regimen with a Fixed Treatment Duration  
Product Theaters


Emerging AstraZeneca Hematology Pipeline  
Industry Theaters


Evolving Treatment Expectations in PNH  
Product Theaters


Investigating the Biological Mechanisms of HR-MDS: Role of the Immune System During Disease  
Industry Theaters


Pfizer Oncology: Pursuing Scientific Breakthroughs for Patients With Hematologic Malignancies  
Industry Theaters


Treatment Data for Relapsed/Refractory Multiple Myeloma and a Focus on How Multiple Myeloma Impacts African American Patients  
Product Theaters

11:35 AM-11:45 AM


Fix the Way You Sit  
ASH Wellness Studio

12:00 PM-1:30 PM


331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological I  
Oral and Poster Abstracts


332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Controversies in Anticoagulation and Venous Thromboembolism  
Oral and Poster Abstracts


605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting Transcription, Translation, and Epigenetics  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Clinical and Epidemiological: Treatment of CNS Lymphoma, Neurologic Toxicities, and Relapsed/Refractory DLBCL  
Oral and Poster Abstracts


653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Bispecific Monoclonal Antibodies in Myeloma  
Oral and Poster Abstracts


704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Lymphoma  
Oral and Poster Abstracts


905. Outcomes Research—Lymphoid Malignancies: Health Outcomes in Plasma Cell Disorders and Transplant  
Oral and Poster Abstracts

12:30 PM-1:30 PM


Ham-Wasserman Lecture  
General Sessions

1:00 PM-3:00 PM


2022 World Cup Soccer Viewing (Outdoors)  
Events

1:30 PM-1:45 PM


Powering Better Decisions: A Comprehensive Hematopathology Analysis Case Study  
Company Showcases

1:30 PM-2:00 PM


Coffee Break in Exhibit Hall (for in-person participants)  
Events


Strategies to Overcome Healthcare Disparities  
Health Equity Studio

1:35 PM-1:45 PM


A Simple Way to More Resilience  
ASH Wellness Studio

1:45 PM-1:55 PM


Financial Order of Operations  
ASH Wellness Studio

2:00 PM-3:00 PM


Blood Advances Meet the Editors  
Special-Interest Sessions

2:00 PM-3:15 PM


Biology and Translation of NK Cells  
Scientific Symposia


Genetic and Functional Heterogeneity in Megakaryocytes and Platelets  
Scientific Symposia


Late Effects of Curative Therapy for Sickle Cell Disease  
Education Program


Overcoming T-cell Burnout and Exhaustion  
Scientific Program


Prophylactic Platelet Transfusions  
Education Program


Thrombosis and Anticoagulation: Clinical Considerations in Selected Populations  
Education Program


Von Willebrand Disease  
Education Program


Where Are We Headed in Hodgkin Lymphoma?  
Education Program

2:00 PM-3:30 PM


113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Cognitive Deficit, Pain, and Inflammation in Sickle Cell Disease: What We Learned from Mouse Models  
Oral and Poster Abstracts


114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Hydroxyurea Treatment  
Oral and Poster Abstracts


322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Looking Forward: Novel Therapies and Diagnostic Modalities for Bleeding Disorders II  
Oral and Poster Abstracts


508. Bone Marrow Failure: Acquired: Biology  
Oral and Poster Abstracts


604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Targeted Protein Degradation and Emerging Small Molecule Inhibitors in Myeloid Neoplasms  
Oral and Poster Abstracts


605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeting BH3, BTK, and CDK  
Oral and Poster Abstracts


614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Clinical Trials  
Oral and Poster Abstracts


615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: New Approaches to Combination Chemotherapy and Venetoclax Plus Hypomethylating Agent Therapy in AML  
Oral and Poster Abstracts


617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Genomic Lesions and Therapeutic Implications  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III  
Oral and Poster Abstracts


634. Myeloproliferative Syndromes: Clinical and Epidemiological: Latest Data for Combination and Emerging Targeted Therapies in Myelofibrosis  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational II  
Oral and Poster Abstracts


652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Relapsed and/or Refractory Myeloma (RRMM)  
Oral and Poster Abstracts


703. Cellular Immunotherapies: Basic and Translational I  
Oral and Poster Abstracts


705. Cellular Immunotherapies: Novel Predictors of Response or Toxicity to Cellular Therapies  
Oral and Poster Abstracts


732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Clinical Outcome: Real World Studies Based on Database Analyses  
Oral and Poster Abstracts


802. Chemical Biology and Experimental Therapeutics I  
Oral and Poster Abstracts


906. Outcomes Research—Myeloid Malignancies II  
Oral and Poster Abstracts


Classification Clarification: Consensus and Compromise  
Special-Interest Sessions


Special Symposium on Quality: Quality Improvement Education and Training  
Special-Interest Sessions

3:30 PM-4:00 PM


Coffee Break in Exhibit Hall (for in-person participants)  
Events


Recognizing and Addressing Implicit Bias  
Health Equity Studio

3:35 PM-3:45 PM


Workday Tension Timeout  
ASH Wellness Studio

3:45 PM-3:55 PM


Use Your Character Strengths to Get Through Trying Times  
ASH Wellness Studio

4:00 PM-5:15 PM


Anxiety Provoking Consultations: Mast Cells and Eosinophils  
Education Program


Are Alternative Donors Now Mainstream in Allogeneic Transplant?  
Education Program


Immunotherapy in Multiple Myeloma  
Education Program


Managing Thrombocytopenia in Challenging Situations  
Education Program


Novel Approaches in MDS  
Education Program


Update in Hemophilia  
Education Program

4:00 PM-5:30 PM


101. Red Cells and Erythropoiesis, Excluding Iron I  
Oral and Poster Abstracts


508. Bone Marrow Failure: Acquired: Clinical Studies  
Oral and Poster Abstracts


602. Myeloid Oncogenesis: Basic: Chromatin Organization and Metabolism  
Oral and Poster Abstracts


617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Molecular Features and Response to Treatment in AML  
Oral and Poster Abstracts


621. Lymphomas: Translational—Molecular and Genetic: Single Cell, Microenvironment, and Treatment Resistance  
Oral and Poster Abstracts


624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Advanced Stage and Relapsed Hodgkin Lymphoma  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Clinical and Epidemiological: Prognostication and Risk Stratification of Aggressive B-cell NHL  
Oral and Poster Abstracts


631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Identification of Novel Therapeutic Targets in MPN and CML  
Oral and Poster Abstracts


632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Molecular Predictors and Advanced Phase Disease  
Oral and Poster Abstracts


634. Myeloproliferative Syndromes: Clinical and Epidemiological: Avant-garde and Traditional Prognostic and Response Assessment in MPNs  
Oral and Poster Abstracts


642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Triplet Combinations and Richter’s Transformation  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational III  
Oral and Poster Abstracts


703. Cellular Immunotherapies: Basic and Translational II  
Oral and Poster Abstracts


704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR T in Multiple Myeloma and T-cell Therapies After Allo-HCT  
Oral and Poster Abstracts


721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities III  
Oral and Poster Abstracts


723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence II  
Oral and Poster Abstracts


905. Outcomes Research—Lymphoid Malignancies: Patient Representation and Equity in Hematologic Malignancies  
Oral and Poster Abstracts


906. Outcomes Research—Myeloid Malignancies I  
Oral and Poster Abstracts


Special Interest Session on Sickle Cell Disease Centers: Ensuring Appropriate Care Across the Patient Lifespan  
Special-Interest Sessions

4:00 PM-5:35 PM


JOINT Session: New Tools to Optimize Platelet Transfusion Therapy  
Scientific Program


JOINT Session - Seed and Soil: The Role of Inflammation in Myeloid Malignancies  
Scientific Program

5:30 PM-7:30 PM


Poster Session I - Presentations  
Events


Welcome Reception in Poster Hall (for in-person participants)  
Events


101. Red Cells and Erythropoiesis, Excluding Iron: Poster I  
Oral and Poster Abstracts


102. Iron Homeostasis and Biology: Poster I  
Oral and Poster Abstracts


112. Thalassemia and Globin Gene Regulation: Poster I  
Oral and Poster Abstracts


113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster I  
Oral and Poster Abstracts


114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


201. Granulocytes, Monocytes, and Macrophages: Poster I  
Oral and Poster Abstracts


203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I  
Oral and Poster Abstracts


301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I  
Oral and Poster Abstracts


311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


321. Coagulation and Fibrinolysis: Basic and Translational: Poster I  
Oral and Poster Abstracts


322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


401. Blood Transfusion: Poster I  
Oral and Poster Abstracts


501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I  
Oral and Poster Abstracts


503. Clonal Hematopoiesis, Aging and Inflammation: Poster I  
Oral and Poster Abstracts


506. Bone Marrow Microenvironment: Poster I  
Oral and Poster Abstracts


508. Bone Marrow Failure: Acquired: Poster I  
Oral and Poster Abstracts


509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I  
Oral and Poster Abstracts


602. Myeloid Oncogenesis: Basic: Poster I  
Oral and Poster Abstracts


603. Lymphoid Oncogenesis: Basic: Poster I  
Oral and Poster Abstracts


604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I  
Oral and Poster Abstracts


605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I  
Oral and Poster Abstracts


612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I  
Oral and Poster Abstracts


615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I  
Oral and Poster Abstracts


616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I  
Oral and Poster Abstracts


617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I  
Oral and Poster Abstracts


618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I  
Oral and Poster Abstracts


621. Lymphomas: Translational—Molecular and Genetic: Poster I  
Oral and Poster Abstracts


622. Lymphomas: Translational–Non-Genetic: Poster I  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I  
Oral and Poster Abstracts


632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


636. Myelodysplastic Syndromes—Basic and Translational: Poster I  
Oral and Poster Abstracts


637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster I  
Oral and Poster Abstracts


642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I  
Oral and Poster Abstracts


652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster I  
Oral and Poster Abstracts


701. Experimental Transplantation: Basic and Translational: Poster I  
Oral and Poster Abstracts


703. Cellular Immunotherapies: Basic and Translational: Poster I  
Oral and Poster Abstracts


704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I  
Oral and Poster Abstracts


705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I  
Oral and Poster Abstracts


711. Cell Collection and Processing: Poster I  
Oral and Poster Abstracts


721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I  
Oral and Poster Abstracts


722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I  
Oral and Poster Abstracts


723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster I  
Oral and Poster Abstracts


731. Autologous Transplantation: Clinical and Epidemiological: Poster I  
Oral and Poster Abstracts


732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I  
Oral and Poster Abstracts


801. Gene Therapies: Poster I  
Oral and Poster Abstracts


802. Chemical Biology and Experimental Therapeutics: Poster I  
Oral and Poster Abstracts


803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster I  
Oral and Poster Abstracts


901. Health Services and Quality—Non-Malignant Conditions: Poster I  
Oral and Poster Abstracts


902. Health Services and Quality—Lymphoid Malignancies: Poster I  
Oral and Poster Abstracts


903. Health Services and Quality–Myeloid Malignancies: Poster I  
Oral and Poster Abstracts


904. Outcomes Research—Non-Malignant Conditions: Poster I  
Oral and Poster Abstracts


905. Outcomes Research—Lymphoid Malignancies: Poster I  
Oral and Poster Abstracts


906. Outcomes Research—Myeloid Malignancies: Poster I  
Oral and Poster Abstracts

6:30 PM-8:00 PM


Promoting Minorities in Hematology Oral Presentations Jefferson Ballroom - Classical Hematology  
Special-Interest Sessions


Promoting Minorities in Hematology Oral Presentations St. Charles Ballroom - Malignant Hematology  
Special-Interest Sessions


Promoting Minorities in Hematology Oral Presentations St. James Ballroom - Outcomes/Health Services  
Special-Interest Sessions

8:00 PM-9:00 PM


Promoting Minorities in Hematology Reception  
Special-Interest Sessions

Sunday, December 11, 2022

Thursday | Friday | Saturday | Sunday | Monday | Tuesday | Wednesday | Thursday | top

7:00 AM-9:00 AM


ASH Foundation Run/Walk  
Events

7:00 AM-5:00 PM


ASH COVID-19 Testing Center (for in-person participants)  
Events


ASH COVID-19 Testing Center (for in-person participants)  
Events


Registration (for in-person participants)  
Events

7:30 AM-9:30 AM


Medical Educators’ Symposium  
Special-Interest Sessions

8:00 AM-9:00 AM


A Discussion on a Treatment Option for Sickle Cell Disease  
Product Theaters


A Treatment Option for Patients with Myelodysplastic Syndromes  
Product Theaters


CANCELLED - vWD and Other Bleeding Disorders – Diagnostic Pitfalls and Special Situations  
How I Treat: Bringing Science to Clinical Dilemmas


CAR -T Cell Analysis and Lymphoma Genomics  
Meet the Scientist


Coffee and Collaboration in ASH Central (for in-person participants)  
Events


Gene Therapy for Hemophilia B: A look into new advancements  
Product Theaters


Gene Therapy for the Hemoglobinopathies: Translating Complex Science to Inform the Physician-Patient Dialogue  
Industry Theaters


Hematopoietic Cell Competition  
Meet the Scientist


Navigating a Career in Hematology and Stem Cell Research  
Meet the Scientist


Pivotal Phase 3 data in newly diagnosed AML: Exploring the efficacy, safety, and patient management of evolving AML treatment paradigms  
Product Theaters


Sanofi Hematology Clinical Pipeline  
Industry Theaters


Thrombosis and Anticoagulation – Duration of Therapy, Thrombophilia - Sunday  
How I Treat: Bringing Science to Clinical Dilemmas


Too Many Mast Cells and Eosinophils – How to Exclude (or Treat) Neoplastic Causes.  
How I Treat: Bringing Science to Clinical Dilemmas


Tumor Cell Imaging  
Meet the Scientist

9:00 AM-9:30 AM


Coffee Break in Poster Hall (for in-person participants)  
Events


Overcoming Disparities in Career Development  
Health Equity Studio

9:00 AM-8:00 PM


Poster Session II - Viewing  
Events

9:05 AM-9:15 AM


Build a Bigger Brain and Longer Life  
ASH Wellness Studio

9:15 AM-9:25 AM


Use Your Character Strengths to Get Through Trying Times  
ASH Wellness Studio

9:30 AM-10:45 AM


Acute Myeloid Leukemia: Improving Outcomes in Challenging Subsets  
Education Program


Building Dietary Evidence for Hematologic Malignancies - Mechanistic Insights  
Scientific Symposia


Maximizing Outcomes in CLL  
Education Program


Reproductive and Sexual Health in Sickle Cell Disease  
Education Program


Targeting Endogenous Retroelements and Viral Mimicry in Therapy of Hematologic Malignancies  
Scientific Symposia

9:30 AM-11:00 AM


113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Targeting the Red Blood Cell: Novel Therapeutic Approaches in Sickle Cell Disease  
Oral and Poster Abstracts


321. Coagulation and Fibrinolysis: Basic and Translational I  
Oral and Poster Abstracts


503. Clonal Hematopoiesis, Aging and Inflammation: Insights from Animal Models  
Oral and Poster Abstracts


509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: From Biology to Therapeutics  
Oral and Poster Abstracts


603. Lymphoid Oncogenesis: Basic: Mechanisms in Leukemogenesis  
Oral and Poster Abstracts


613. Acute Myeloid Leukemias: Clinical and Epidemiological: Clinical Care and Observations in Acute Myeloid Leukemia  
Oral and Poster Abstracts


617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Treatment-related Biomarkers  
Oral and Poster Abstracts


618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: B-lineage ALL: Molecular Characterization and Targeted Therapies  
Oral and Poster Abstracts


626. Aggressive Lymphomas: Prospective Therapeutic Trials: Immune Based and Targeted Therapies in Relapsed/Refractory Large B-Cell Lymphoma  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Clinical and Epidemiological: Rare Populations  
Oral and Poster Abstracts


631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Molecular Consequences of MPN Driver and Co-mutations  
Oral and Poster Abstracts


637. Myelodysplastic Syndromes – Clinical and Epidemiological III  
Oral and Poster Abstracts


652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Factors in Newly Diagnosed Multiple Myeloma (NDMM)  
Oral and Poster Abstracts


701. Experimental Transplantation: Basic and Translational: Novel Mechanisms of Acute and Chronic Graft-versus-Host Disease  
Oral and Poster Abstracts


703. Cellular Immunotherapies: Basic and Translational IV  
Oral and Poster Abstracts


731. Autologous Transplantation: Clinical and Epidemiological: Lymphoma, AML, and Multiple Sclerosis  
Oral and Poster Abstracts


803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: New Molecular Tools for Precision Diagnostics in Hematology  
Oral and Poster Abstracts


901. Health Services and Quality—Non-Malignant Conditions: Cell Line Down! Optimizing Diagnosis and Management of Isolated Cytopenias  
Oral and Poster Abstracts


904. Outcomes Research—Non-Malignant Conditions: Classical Hematology: From Horses to Zebras  
Oral and Poster Abstracts


ASH Guideline Implementation Champions  
Special-Interest Sessions

9:30 AM-11:05 AM


JOINT Session - Cell Competition and Clonal Hematopoiesis  
Scientific Program


JOINT Session - The Lymphoma Microenvironment and Its Impact on Therapy  
Scientific Program

10:00 AM-5:00 PM


Exhibits Open  
Events

11:00 AM-12:30 PM


Complimentary Light Lunch in the Exhibit Hall (for in-person participants)  
Events


Live Music and Outdoor Lunch Seating (for in-person participants)  
Events

11:05 AM-11:15 AM


Coping With Financial Strain and Gain  
ASH Wellness Studio

11:15 AM-11:45 AM


Strategies to Improve Diversity and Inclusion in Healthcare and Industry  
Health Equity Studio

11:15 AM-12:00 PM


Meet the Blood Editors  
Special-Interest Sessions

11:15 AM-12:15 PM


Blood Advances Presents: How to Peer Review a Scientific Paper  
Special-Interest Sessions


LGBTQIA+ Community Networking Brunch  
Special-Interest Sessions


Trainee Didactic Session: How to Transition from Trainee to Faculty
Trainee Activities and Services


Trainee Didactic Session: Writing a Good CV, Portfolio, and Biosketch
Trainee Activities and Services

11:15 AM-12:30 PM


ASH Practice Partnership Lunch - A Return to the Classics: The Need for Classical Hematology  
Special-Interest Sessions

11:20 AM-11:30 AM


Feel Better in Your Body  
ASH Wellness Studio

11:30 AM-12:30 PM


ASH Health Equity Rounds Lunch  
Special-Interest Sessions


Genentech Lymphoma Product Presentation  
Product Theaters


Investigating Nuclear Transport Inhibition in Myelofibrosis (MF) and Myelodysplastic Neoplasms (MDS)  
Industry Theaters


Kite, The Leader in Cell Therapy: Leading the Way in Large B-Cell Lymphoma Care  
Product Theaters


Protection Onboard: A Clinical Approach to Preventing COVID-19 in At-Risk Patients  
Industry Theaters


The clinical actionability of clonoSEQ MRD assessment in lymphoid malignancies  
Product Theaters


Treatment Option in AML  
Product Theaters


What's Next for Patients with Relapsed or Refractory Multiple Myeloma after Multiple Lines of Therapy?  
Product Theaters

11:35 AM-11:45 AM


Regulate Your Genes for More Energy and Less Inflammation  
ASH Wellness Studio

12:00 PM-1:30 PM


101. Red Cells and Erythropoiesis, Excluding Iron II  
Oral and Poster Abstracts


332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Cancer-associated Thrombosis: Risk Stratification, Prevention, and Treatment  
Oral and Poster Abstracts


506. Bone Marrow Microenvironment: Contribution of Immune Signaling to the Microenvironment  
Oral and Poster Abstracts


602. Myeloid Oncogenesis: Basic: Epigenetics and Transcriptional Regulation  
Oral and Poster Abstracts


613. Acute Myeloid Leukemias: Clinical and Epidemiological: Long-term Outcomes in Clinically Defined Subgroups of Patients with Acute Myeloid Leukemia  
Oral and Poster Abstracts


621. Lymphomas: Translational—Molecular and Genetic: ctDNA and Prognostication  
Oral and Poster Abstracts


622. Lymphomas: Translational–Non-Genetic: Translational Research in Lymphoma: Prognostic Biomarkers and Novel Therapeutic Vulnerabilities  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Clinical and Epidemiological: Real World Evidence for Management of CNS Lymphoma and Post CAR T-cell relapse for aggressive B-cell NHL  
Oral and Poster Abstracts


637. Myelodysplastic Syndromes – Clinical and Epidemiological IV  
Oral and Poster Abstracts


653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Novel Drugs and Optimized Approaches in Myeloma  
Oral and Poster Abstracts


722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Critical Advances in GVHD Management  
Oral and Poster Abstracts


904. Outcomes Research—Non-Malignant Conditions: Sickle Cell Disease Therapies & Outcomes  
Oral and Poster Abstracts

12:30 PM-12:59 PM


Defining Inequity and Root Causes of Health Inequities  
Health Equity Studio

12:30 PM-1:30 PM


ASH-EHA Joint Symposium  
General Sessions

1:30 PM-2:00 PM


Announcement of Awards: Wallace H. Coulter Award for Lifetime Achievement in Hematology, ASH Mentor Awards, ASH Award for Leadership in Promoting Diversity, ASH Outstanding Service Award, and ASH Public Service Award  
General Sessions

2:00 PM-4:00 PM


Plenary Scientific Session  
General Sessions

4:00 PM-4:15 PM


AML single-cell multi-omics MRD (scMRD) and the horizon of clinical utility  
Company Showcases

4:00 PM-4:30 PM


Coffee Break in Exhibit Hall (for in-person participants)  
Events


Overcoming Lack of Diversity in Clinical Trials  
Health Equity Studio

4:05 PM-4:15 PM


The Greatest Medicine...A True Friend  
ASH Wellness Studio

4:15 PM-4:25 PM


Fix the Way You Sit  
ASH Wellness Studio

4:30 PM-5:45 PM


Beyond Routine Frontline Therapy of CML  
Education Program


Bone Marrow Failure Syndromes: Diagnostic Principles in 2022  
Spotlight Sessions


New Horizons for Histiocyte Disorders  
Spotlight Sessions


New Therapeutic Targets for Thrombosis That Do Not Cause Bleeding  
Scientific Program


Obstetric Management and Complications in Sickle Cell Disease in High- and Low-Income Countries  
Education Program


Platelet Factor 4-Mediated Immunothrombosis: Insights from the Novel Syndrome of Vaccine-Induced Thrombosis and Thrombocytopenia (VITT)  
Spotlight Sessions


Survivorship in adult patients with lymphoma  
Spotlight Sessions


What's New in Indolent Lymphoma  
Education Program

4:30 PM-6:00 PM


201. Granulocytes, Monocytes, and Macrophages I  
Oral and Poster Abstracts


322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Von Willebrand Disease and Other Congenital and Acquired Bleeding Disorders  
Oral and Poster Abstracts


613. Acute Myeloid Leukemias: Clinical and Epidemiological: Genomic Determinants of Prognosis in Patients with Acute Myeloid Leukemia  
Oral and Poster Abstracts


615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Outcomes and New Treatment Strategies in Genetically Adverse Risk and MRD-positive AML  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological IV  
Oral and Poster Abstracts


624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Mature T-cell Malignancies: Clinical and Epidemiological  
Oral and Poster Abstracts


632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Longer Term Response, TFR, Pregnancy, and Disparities  
Oral and Poster Abstracts


634. Myeloproliferative Syndromes: Clinical and Epidemiological: Towards Personalized Medicine in Myeloproliferative Neoplasms and Mastocytosis: New and Repurposed Drugs for Unmet Clinical Needs  
Oral and Poster Abstracts


637. Myelodysplastic Syndromes – Clinical and Epidemiological II  
Oral and Poster Abstracts


641. Chronic Lymphocytic Leukemias: Basic and Translational: Pathogenesis and Transformation  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational: Genomic Markers of Disease Progression and Therapeutic Response  
Oral and Poster Abstracts


652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Markers in Multiple Myeloma  
Oral and Poster Abstracts


701. Experimental Transplantation: Basic and Translational: Novel Translational Approaches in Transplantation  
Oral and Poster Abstracts


705. Cellular Immunotherapies: Results from CD19-Directed CAR T in treating Aggressive B-cell Lymphomas  
Oral and Poster Abstracts


711. Cell Collection and Processing I  
Oral and Poster Abstracts


901. Health Services and Quality—Non-Malignant Conditions: Better, Faster, Stronger: Innovations in Care Delivery, Care Cost, and Healthcare Teams in Classical Hematology  
Oral and Poster Abstracts


ASH Guidelines on VTE: Prevention and Treatment in Patients with Cancer  
Special-Interest Sessions


Blood and Beyond  
Special-Interest Sessions

4:30 PM-6:30 PM


Systems-Based Hematology Education and Networking Session  
Special-Interest Sessions

6:00 PM-8:00 PM


Poster Hall Reception (for in-person participants)  
Events


Poster Session II - Presentations  
Events


101. Red Cells and Erythropoiesis, Excluding Iron: Poster II  
Oral and Poster Abstracts


102. Iron Homeostasis and Biology: Poster II  
Oral and Poster Abstracts


112. Thalassemia and Globin Gene Regulation: Poster II  
Oral and Poster Abstracts


113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster II  
Oral and Poster Abstracts


114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


201. Granulocytes, Monocytes, and Macrophages: Poster II  
Oral and Poster Abstracts


203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II  
Oral and Poster Abstracts


301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster II  
Oral and Poster Abstracts


311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


321. Coagulation and Fibrinolysis: Basic and Translational: Poster II  
Oral and Poster Abstracts


322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


401. Blood Transfusion: Poster II  
Oral and Poster Abstracts


501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II  
Oral and Poster Abstracts


503. Clonal Hematopoiesis, Aging and Inflammation: Poster II  
Oral and Poster Abstracts


506. Bone Marrow Microenvironment: Poster II  
Oral and Poster Abstracts


508. Bone Marrow Failure: Acquired: Poster II  
Oral and Poster Abstracts


509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II  
Oral and Poster Abstracts


602. Myeloid Oncogenesis: Basic: Poster II  
Oral and Poster Abstracts


603. Lymphoid Oncogenesis: Basic: Poster II  
Oral and Poster Abstracts


604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II  
Oral and Poster Abstracts


605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II  
Oral and Poster Abstracts


612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II  
Oral and Poster Abstracts


615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II  
Oral and Poster Abstracts


616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II  
Oral and Poster Abstracts


617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II  
Oral and Poster Abstracts


618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II  
Oral and Poster Abstracts


621. Lymphomas: Translational—Molecular and Genetic: Poster II  
Oral and Poster Abstracts


622. Lymphomas: Translational–Non-Genetic: Poster II  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster II  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II  
Oral and Poster Abstracts


632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


636. Myelodysplastic Syndromes—Basic and Translational: Poster II  
Oral and Poster Abstracts


637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster II  
Oral and Poster Abstracts


642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II  
Oral and Poster Abstracts


652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II  
Oral and Poster Abstracts


701. Experimental Transplantation: Basic and Translational: Poster II  
Oral and Poster Abstracts


703. Cellular Immunotherapies: Basic and Translational: Poster II  
Oral and Poster Abstracts


704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II  
Oral and Poster Abstracts


705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II  
Oral and Poster Abstracts


711. Cell Collection and Processing: Poster II  
Oral and Poster Abstracts


721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II  
Oral and Poster Abstracts


722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II  
Oral and Poster Abstracts


723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster II  
Oral and Poster Abstracts


731. Autologous Transplantation: Clinical and Epidemiological: Poster II  
Oral and Poster Abstracts


732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II  
Oral and Poster Abstracts


801. Gene Therapies: Poster II  
Oral and Poster Abstracts


802. Chemical Biology and Experimental Therapeutics: Poster II  
Oral and Poster Abstracts


803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster II  
Oral and Poster Abstracts


901. Health Services and Quality—Non-Malignant Conditions: Poster II  
Oral and Poster Abstracts


902. Health Services and Quality—Lymphoid Malignancies: Poster II  
Oral and Poster Abstracts


903. Health Services and Quality–Myeloid Malignancies: Poster II  
Oral and Poster Abstracts


904. Outcomes Research—Non-Malignant Conditions: Poster II  
Oral and Poster Abstracts


905. Outcomes Research—Lymphoid Malignancies: Poster II  
Oral and Poster Abstracts


906. Outcomes Research—Myeloid Malignancies: Poster II  
Oral and Poster Abstracts

Monday, December 12, 2022

Thursday | Friday | Saturday | Sunday | Monday | Tuesday | Wednesday | Thursday | top

7:00 AM-7:45 AM


ASH Yoga  
ASH Wellness Studio

7:00 AM-5:00 PM


ASH COVID-19 Testing Center (for in-person participants)  
Events


ASH COVID-19 Testing Center (for in-person participants)  
Events


Registration (for in-person participants)  
Events

7:30 AM-9:00 AM


Disability Community Networking Breakfast  
Special-Interest Sessions

8:00 AM-9:00 AM


A breakthrough for patients: Complement inhibition in Cold Agglutinin Disease  
Product Theaters


Coffee and Collaboration in ASH Central (for in-person participants)  
Events


First and Only: VONVENDI® [von Willebrand factor (recombinant)] for Prophylaxis and More  
Product Theaters


Multidisciplinary Discussion on Incorporating IMBRUVICA® (ibrutinib) Into Treatment Strategies  
Product Theaters


Perspectives on the Treatment of DVT/PE, Including Those Patients with Obesity and/or Cancer  
Product Theaters


ZYNLONTA®: The First and Only CD19-Directed ADC For 3L DLBCL  
Product Theaters

9:00 AM-10:00 AM


E. Donnall Thomas Lecture and Prize  
General Sessions

9:00 AM-8:00 PM


Poster Session III - Viewing  
Events

10:00 AM-10:30 AM


Coffee Break in Exhibit Hall (for in-person participants)  
Events


Strategies to Overcome Healthcare Disparities  
Health Equity Studio

10:00 AM-2:00 PM


Exhibits Open  
Events

10:05 AM-10:15 AM


Bringing Joy to Your World  
ASH Wellness Studio

10:15 AM-10:25 AM


The Real Purpose of Your Purpose  
ASH Wellness Studio

10:15 AM-10:30 AM


PICKUP Study: Pneumonia in the ImmunoCompromised – Use of the Karius Test® for the Detection of Undiagnosed Pathogens  
Company Showcases

10:30 AM-11:45 AM


Childhood Red Cell Disorders: Embracing Technology to Improve How We Manage Challenging Anemias  
Scientific Program


Debate: Most/All Patients with Acquired (Immune) Thrombotic Thrombocytopenic Purpura Receive Caplacizumab  
Spotlight Sessions


Improving Outcomes in ALL  
Education Program


Plasma Cell Dyscrasias: Resistance to Immunotherapy: Mechanisms and Monitoring  
Scientific Program


Underrepresented minorities in clinical trials for hematologic malignancies: what's the data on the data?  
Spotlight Sessions

10:30 AM-12:00 PM


114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Organ Function  
Oral and Poster Abstracts


203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Delineating Immunity from Mice to Humans  
Oral and Poster Abstracts


301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Thrombosis and the Endothelium  
Oral and Poster Abstracts


321. Coagulation and Fibrinolysis: Basic and Translational II  
Oral and Poster Abstracts


506. Bone Marrow Microenvironment: Extrinsic Regulators of Hematopoiesis  
Oral and Poster Abstracts


603. Lymphoid Oncogenesis: Basic: Mechanisms in Lymphomagenesis  
Oral and Poster Abstracts


616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Frontline and Maintenance  
Oral and Poster Abstracts


618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: High-risk T-ALL and Prognostic Biomarkers  
Oral and Poster Abstracts


621. Lymphomas: Translational—Molecular and Genetic: Genomic Characterization  
Oral and Poster Abstracts


624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Hodgkin Lymphoma: Retrospective Analyses and Prospective Trials  
Oral and Poster Abstracts


626. Aggressive Lymphomas: Prospective Therapeutic Trials: Frontline Treatment of Large B-cell Lymphoma  
Oral and Poster Abstracts


634. Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies and Surrogate Endpoints in ET and PV  
Oral and Poster Abstracts


641. Chronic Lymphocytic Leukemias: Basic and Translational: Novel Therapies and Biomarkers  
Oral and Poster Abstracts


652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Therapeutic Impact in Multiple Myeloma  
Oral and Poster Abstracts


653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Risk-adapted Treatment Strategies in Myeloma and Related Conditions  
Oral and Poster Abstracts


705. Cellular Immunotherapies: Real World Outcomes and Special Populations Treated with Cellular Therapy  
Oral and Poster Abstracts


722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Novel Therapies for Graft-versus-Host Disease  
Oral and Poster Abstracts


723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence I  
Oral and Poster Abstracts


801. Gene Therapies: Advances in Clinical Gene Therapy for Hematological Disorders  
Oral and Poster Abstracts


803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Clinical Implication of Artificial Intelligence in Precision Hematology  
Oral and Poster Abstracts


905. Outcomes Research—Lymphoid Malignancies: Outcomes in Lymphoma  
Oral and Poster Abstracts


ASH-FDA Joint Symposium: Something Old, Something New - Recent Immunotherapy and Targeted Agent Approvals  
Special-Interest Sessions


Maternal Health in Hematology - Current Resources and Future Advocacy  
Special-Interest Sessions

12:00 PM-1:30 PM


Complimentary Light Lunch in the Exhibit Hall (for in-person participants)  
Events


Live Music and Outdoor Lunch Seating (for in-person participants)  
Events

12:05 PM-12:15 PM


Build a Bigger Brain and Longer Life  
ASH Wellness Studio

12:15 PM-12:45 PM


Recognizing and Addressing Implicit Bias  
Health Equity Studio

12:15 PM-1:00 PM


Meet the Blood Editors  
Special-Interest Sessions

12:15 PM-1:15 PM


A clinical overview of REZLIDHIA (olutasidenib): A Newly Approved Therapy for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation  
Product Theaters


An Innovative Treatment Option for Appropriate Patients With cGVHD  
Product Theaters


ASH Choosing Wisely® Campaign: 2022 ASH Choosing Wisely Champions  
Special-Interest Sessions


From Science Fiction to Standard of Care: Developing the next wave of Genomic Medicines for Hematology  
Industry Theaters


Frontline Treatment of Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Across Patient Types  
Product Theaters


Trainee Didactic Session: Entrepreneurship
Trainee Activities and Services


Trainee Didactic Session: Giving A Scientific Presentation
Trainee Activities and Services


VelociSuite: Leveraging Regeneron’s Technologies to Produce an Innovative Therapeutic Pipeline  
Industry Theaters

12:20 PM-12:30 PM


Amplify Your Heart Brain for Improved Cognitive Function and Emotional Stability  
ASH Wellness Studio

12:35 PM-12:45 PM


Feel Better in Your Body  
ASH Wellness Studio

1:00 PM-1:30 PM


Overcoming Disparities in Career Development  
Health Equity Studio

1:30 PM-2:30 PM


Ernest Beutler Lecture and Prize  
General Sessions

2:30 PM-2:45 PM


Coffee Break in Exhibit Hall (for in-person participants)  
Events

2:30 PM-3:00 PM


Strategies to Improve Diversity and Inclusion in Healthcare and Industry  
Health Equity Studio

2:35 PM-2:45 PM


Straight Spine, Big Smile  
ASH Wellness Studio

2:45 PM-4:00 PM


Histone Modifications and Chromatin Programs in Clonal Selection and Cancer Emergence  
Scientific Program


Immunotherapies for myeloid neoplasms: are we ready for primetime?  
Spotlight Sessions


Iron and Red Cells: A Co-Dependent Relationship  
Scientific Program


Morphology in a Genomic World  
Scientific Program


Point/Counterpoint: The case for/against thrombophilia testing in many/most adults with unprovoked thrombosis.  
Spotlight Sessions


Sowing the Seeds of Leukemia Before Birth  
Spotlight Sessions


Treatment Approaches for the Multiple Myeloma Patient in 2022  
Education Program


Updates in Targeted Therapy in Pediatric Leukemia  
Education Program


What is New in Classical Bone Marrow Failure Syndromes? (focus on management)  
Education Program

2:45 PM-4:15 PM


112. Thalassemia and Globin Gene Regulation I  
Oral and Poster Abstracts


114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Women's and Clinical Issues  
Oral and Poster Abstracts


301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Mechanistic Insights That Suggest Novel Diagnostic or Therapeutic Strategies  
Oral and Poster Abstracts


501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Basic and Developmental  
Oral and Poster Abstracts


602. Myeloid Oncogenesis: Basic: DNA Damage and Genetic Evolution  
Oral and Poster Abstracts


615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Advances in Mutation-targeted Therapy for AML  
Oral and Poster Abstracts


617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Venetoclax, HMA, and Response to Treatment in AML  
Oral and Poster Abstracts


621. Lymphomas: Translational—Molecular and Genetic: Functional Genomics and Biology  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Clinical and Epidemiological: Predictors of Outcome  
Oral and Poster Abstracts


637. Myelodysplastic Syndromes – Clinical and Epidemiological I  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational: Novel Therapeutic Strategies, Characterization of Response Biology, and Consequences  
Oral and Poster Abstracts


652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: New Approaches to MRD Assessment  
Oral and Poster Abstracts


721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities II  
Oral and Poster Abstracts


732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Clinical Outcome: Results of Large Prospective Studies  
Oral and Poster Abstracts


901. Health Services and Quality—Non-Malignant Conditions: Level Up! Taking Quality Care to the Next Level in Sickle Cell Disease  
Oral and Poster Abstracts


902. Health Services and Quality—Lymphoid Malignancies: Real World Consequences and Cost of Care  
Oral and Poster Abstracts


904. Outcomes Research—Non-Malignant Conditions: Sickle Cell Care Across the Lifespan  
Oral and Poster Abstracts


905. Outcomes Research—Lymphoid Malignancies: Outcomes in Childhood Leukemia/Lymphoma  
Oral and Poster Abstracts


Building a Nationwide Sickle Cell Disease Data Hub and Learning Community  
Special-Interest Sessions

4:30 PM-5:45 PM


Junior Faculty Career Development Education Session  
Education Program


Long-Term Effects Monitoring for Survivors of Pediatric Hematologic Malignancies  
Education Program


Metabolic Regulation and Implications for Red Cells  
Scientific Program


Thrombosis Prevention and Treatment  
Education Program


To Transplant or Not to Transplant in Active or High Risk Myeloid Disease  
Education Program

4:30 PM-6:00 PM


102. Iron Homeostasis and Biology I  
Oral and Poster Abstracts


311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Mechanisms and Treatment of ITP  
Oral and Poster Abstracts


501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Disease and Aging  
Oral and Poster Abstracts


503. Clonal Hematopoiesis, Aging and Inflammation: Insights from Human Cohorts And Biosamples  
Oral and Poster Abstracts


604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Immune Signaling and Antibody-therapeutic Targeting in Myeloid Neoplasms  
Oral and Poster Abstracts


605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Therapeutics  
Oral and Poster Abstracts


617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease Detection in AML and Single Cell Investigations  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological II  
Oral and Poster Abstracts


624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Mature T- and NK-cell Lymphomas: Prospective Trials and a Retrospective Analysis  
Oral and Poster Abstracts


642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Drugs in Development and COVID-19  
Oral and Poster Abstracts


652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Disease Monitoring  
Oral and Poster Abstracts


703. Cellular Immunotherapies: Basic and Translational III  
Oral and Poster Abstracts


704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Acute Leukemia and Hodgkin Lymphoma  
Oral and Poster Abstracts


721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities I  
Oral and Poster Abstracts


902. Health Services and Quality—Lymphoid Malignancies: Time for Change: Health Care Delivery and Disparities  
Oral and Poster Abstracts


905. Outcomes Research—Lymphoid Malignancies: Health Outcomes in CAR T and Stem Cell Transplantation  
Oral and Poster Abstracts


ASH-FDA Joint Symposium: Novel Approvals in Non-Malignant Hematology  
Special-Interest Sessions


ASH Guidelines on AML in Older Adults: Monitoring Emerging Evidence  
Special-Interest Sessions


ASH ISTH NHF WFH Guidelines on VWD: Impact on Patients, Policy, and Allied Health Professionals  
Special-Interest Sessions


Driving Real-World Evidence for Hematologic Malignancy Research – A Joint ASH RC and EU HARMONY Session  
Special-Interest Sessions


Special Session: AI and Machine Learning: A New Frontier in Hematology  
Special-Interest Sessions

4:30 PM-6:05 PM


Special Symposium on the Basic Science of Hemostasis and Thrombosis  
Scientific Symposia

6:00 PM-8:00 PM


ASH and the ASH Research Collaborative: Advancing Progress in Sickle Cell Disease Update and Reception  
Special-Interest Sessions


Poster Hall Reception (for in-person participants)  
Events


Poster Session III - Presentations  
Events


101. Red Cells and Erythropoiesis, Excluding Iron: Poster III  
Oral and Poster Abstracts


102. Iron Homeostasis and Biology: Poster III  
Oral and Poster Abstracts


112. Thalassemia and Globin Gene Regulation: Poster III  
Oral and Poster Abstracts


113. Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster III  
Oral and Poster Abstracts


114. Hemoglobinopathies, Excluding Thalassemia: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


201. Granulocytes, Monocytes, and Macrophages: Poster III  
Oral and Poster Abstracts


203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III  
Oral and Poster Abstracts


301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster III  
Oral and Poster Abstracts


311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


321. Coagulation and Fibrinolysis: Basic and Translational: Poster III  
Oral and Poster Abstracts


322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


401. Blood Transfusion: Poster III  
Oral and Poster Abstracts


501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III  
Oral and Poster Abstracts


503. Clonal Hematopoiesis, Aging and Inflammation: Poster III  
Oral and Poster Abstracts


506. Bone Marrow Microenvironment: Poster III  
Oral and Poster Abstracts


508. Bone Marrow Failure: Acquired: Poster III  
Oral and Poster Abstracts


509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III  
Oral and Poster Abstracts


602. Myeloid Oncogenesis: Basic: Poster III  
Oral and Poster Abstracts


603. Lymphoid Oncogenesis: Basic: Poster III  
Oral and Poster Abstracts


604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III  
Oral and Poster Abstracts


605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III  
Oral and Poster Abstracts


612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III  
Oral and Poster Abstracts


615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III  
Oral and Poster Abstracts


616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III  
Oral and Poster Abstracts


617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III  
Oral and Poster Abstracts


618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III  
Oral and Poster Abstracts


621. Lymphomas: Translational—Molecular and Genetic: Poster III  
Oral and Poster Abstracts


622. Lymphomas: Translational–Non-Genetic: Poster III  
Oral and Poster Abstracts


623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III  
Oral and Poster Abstracts


627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III  
Oral and Poster Abstracts


632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


636. Myelodysplastic Syndromes—Basic and Translational: Poster III  
Oral and Poster Abstracts


637. Myelodysplastic Syndromes – Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


641. Chronic Lymphocytic Leukemias: Basic and Translational: Poster III  
Oral and Poster Abstracts


642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III  
Oral and Poster Abstracts


652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster III  
Oral and Poster Abstracts


701. Experimental Transplantation: Basic and Translational: Poster III  
Oral and Poster Abstracts


703. Cellular Immunotherapies: Basic and Translational: Poster III  
Oral and Poster Abstracts


704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III  
Oral and Poster Abstracts


705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster III  
Oral and Poster Abstracts


711. Cell Collection and Processing: Poster III  
Oral and Poster Abstracts


721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster III  
Oral and Poster Abstracts


722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III  
Oral and Poster Abstracts


723. Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence: Poster III  
Oral and Poster Abstracts


731. Autologous Transplantation: Clinical and Epidemiological: Poster III  
Oral and Poster Abstracts


732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III  
Oral and Poster Abstracts


801. Gene Therapies: Poster III  
Oral and Poster Abstracts


802. Chemical Biology and Experimental Therapeutics: Poster III  
Oral and Poster Abstracts


803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: Poster III  
Oral and Poster Abstracts


901. Health Services and Quality—Non-Malignant Conditions: Poster III  
Oral and Poster Abstracts


902. Health Services and Quality—Lymphoid Malignancies: Poster III  
Oral and Poster Abstracts


903. Health Services and Quality–Myeloid Malignancies: Poster III  
Oral and Poster Abstracts


904. Outcomes Research—Non-Malignant Conditions: Poster III  
Oral and Poster Abstracts


905. Outcomes Research—Lymphoid Malignancies: Poster III  
Oral and Poster Abstracts


906. Outcomes Research—Myeloid Malignancies: Poster III  
Oral and Poster Abstracts

6:30 PM-7:30 PM


Hemostasis and Thrombosis Community Networking Reception (for in-person participants)  
Special-Interest Sessions

7:30 PM-9:30 PM


Women in Hematology Networking Dinner  
Special-Interest Sessions

Tuesday, December 13, 2022

Thursday | Friday | Saturday | Sunday | Monday | Tuesday | Wednesday | Thursday | top

7:00 AM-1:30 PM


ASH COVID-19 Testing Center (for in-person participants)  
Events


ASH COVID-19 Testing Center (for in-person participants)  
Events


Registration (for in-person participants)  
Events

8:45 AM-9:00 AM


Announcement of Awards: William Dameshek Prize and Henry M. Stratton Medals  
General Sessions

9:00 AM-10:30 AM


Late-Breaking Abstracts Session  
General Sessions

10:30 AM-11:00 AM


Coffee Available in General Session Room (for in-person participants)  
Events

11:00 AM-12:30 PM


Presidential Symposium  
General Sessions

12:30 PM-2:00 PM


Best of ASH  
General Sessions

2:00 PM-2:15 PM


Business Meeting  
General Sessions

Wednesday, December 14, 2022

Thursday | Friday | Saturday | Sunday | Monday | Tuesday | Wednesday | Thursday | top

10:00 AM-11:00 AM


ASH Poster Walk on Beyond Hematology: Clinical and Mechanistic Links between Clonal Hematopoiesis and Non-Hematological Disorders  
ASH Poster Walks


ASH Poster Walk on What's Hot in Sickle Cell Disease Research 2022  
ASH Poster Walks

5:00 PM-6:00 PM


ASH Poster Walk on Diversity, Equity, and Inclusion in Hematologic Malignancies and Cellular Therapy  
ASH Poster Walks

Thursday, December 15, 2022

Thursday | Friday | Saturday | Sunday | Monday | Tuesday | Wednesday | Thursday | top

10:00 AM-11:00 AM


ASH Poster Walk on The Spectrum of Hemostasis and Thrombosis Research  
ASH Poster Walks

5:00 PM-6:00 PM


ASH Poster Walk on Platelets from Bench to Bedside  
ASH Poster Walks